The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the expression of a ...
Veracyte (VCYT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Puneet Souda ...
Received tentative approval from the FDA for YUTREPIATM (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) ...
Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...
Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...
DelveInsight’s 'Non-Cystic Fibrosis Bronchiectasis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline non-cystic fibrosis bronchiectasis therapies in various stages of ...
A pneumonia cough may sound deeper or louder than other coughs, and you may notice dryness or phlegm. But it also depends on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback